Skip to content
Briakinumab
Briakinumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against interleukin-12 subunit beta.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AC: Interleukin inhibitors
— L04AC09: Briakinumab
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L40115——7
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Crohn diseaseD003424EFO_0000384K5011———2
Multiple sclerosisD009103EFO_0003885G35—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBRIAKINUMAB
INNbriakinumab
Description
Briakinumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)BRIAKINUMAB
Structure (InChI/SMILES or Protein Sequence)
>5N2K:A,C,E,I,K,M,O|Briakinumab FAb light chain MGILPSPGMPALLSLVSLLSVLLMGCVAQSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYN DQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVLGQPKAAPSVTLFPPSSEELQA NKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVA PTECS >5N2K:B,D,F,H,L,N,P|Briakinumab FAb heavy chain MGILPSPGMPALLSLVSLLSVLLMGCVAQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIR YDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK VEPKSCDKGTSGLVPRGSGGSGGSGLNDIFEAQKIEWHEGRTKHHHHHH >5N2K:G|Briakinumab FAb light chain MGILPSPGMPALLSLVSLLSVLLMGCVA(PCA)SVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLL IYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVLGQPKAAPSVTLFPPSSE ELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVE KTVAPTECS >5N2K:J|Briakinumab FAb heavy chain MGILPSPGMPALLSLVSLLSVLLMGCVA(PCA)VQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWV AFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSSASTKGPSVFPLAP SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK VDKKVEPKSCDKGTSGLVPRGSGGSGGSGLNDIFEAQKIEWHEGRTKHHHHHH
Identifiers
PDB5N2K, 5NJD
CAS-ID339308-60-0
RxCUI—
ChEMBL IDCHEMBL1742995
ChEBI ID—
PubChem CID—
DrugBankDB05459
UNII ID978I8M0P8X (ChemIDplus, GSRS)
Target
Agency Approved
IL12B
IL12B
Organism
Homo sapiens
Gene name
IL12B
Gene synonyms
NKSF2
NCBI Gene ID
3593
Protein name
interleukin-12 subunit beta
Protein synonyms
CLMF p40, Cytotoxic lymphocyte maturation factor 40 kDa subunit, IL-12 subunit p40, IL12, subunit p40, interleukin 12, p40, interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40), interleukin-12 beta chain, natural killer cell stimulatory factor, 40 kD subunit, NK cell stimulatory factor chain 2, NKSF2
Uniprot ID
P29460
Mouse ortholog
Il12b (16160)
interleukin-12 subunit beta (Q9QUM1)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 374 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details